CA Stock MarketDetailed Quotes
INNO InnoCan Pharma Corp
- 0.195
- +0.010+5.41%
15min DelayMarket Closed Jan 10 15:56 ET
56.57MMarket Cap-16.25P/E (TTM)
0.195High0.185Low72.50KVolume0.185Open0.185Pre Close13.68KTurnover0.33052wk High0.03%Turnover Ratio290.12MShares0.16052wk Low-0.012EPS TTM43.84MFloat Cap1.650Historical HighLossP/E (Static)224.84MShs Float0.050Historical Low-0.023EPS LYR5.41%Amplitude--Dividend TTM7.50P/B1Lot Size--Div YieldTTM
InnoCan Pharma Corp Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 111.22%8.62M | 176.96%8.64M | 333.85%6.77M | 433.69%13.66M | 331.10%4.89M | 445.13%4.08M | 652.05%3.12M | 500.00%1.56M | 1,205.61%2.56M | 6,993.75%1.14M |
| Operating revenue | 111.22%8.62M | 176.96%8.64M | 333.85%6.77M | 433.69%13.66M | 331.10%4.89M | 445.13%4.08M | 652.05%3.12M | 500.00%1.56M | 1,205.61%2.56M | 6,993.75%1.14M |
| Cost of revenue | 101.67%845K | 38.92%646K | 303.68%767K | 271.46%1.68M | 1,676.47%604K | 1,132.35%419K | 131.34%465K | 4.40%190K | 502.67%452K | 466.67%34K |
| Gross profit | 112.31%7.78M | 201.13%8M | 338.03%6M | 468.49%11.98M | 289.55%4.29M | 412.45%3.66M | 1,141.12%2.66M | 1,656.41%1.37M | 1,641.32%2.11M | 10,910.00%1.1M |
| Operating expense | 52.51%7.43M | 141.46%7.47M | 173.63%7.21M | 88.47%15.78M | 106.49%5.18M | 174.37%4.87M | 41.12%3.09M | 38.96%2.64M | 10.16%8.37M | 9.94%2.51M |
| Selling and administrative expenses | 58.82%7.05M | 148.36%7.04M | 234.10%6.79M | 104.25%13.99M | 117.32%4.68M | 187.69%4.44M | 63.78%2.84M | 43.10%2.03M | 10.40%6.85M | 9.18%2.15M |
| -Selling and marketing expense | 88.52%6.1M | 168.20%5.95M | 313.16%4.99M | 265.54%10.47M | 276.56%3.81M | 350.91%3.23M | 179.60%2.22M | 253.22%1.21M | 103.84%2.86M | 101.80%1.01M |
| -General and administrative expense | -20.81%955K | 76.75%1.09M | 118.20%1.8M | -11.72%3.52M | -23.64%872K | 46.00%1.21M | -34.36%615K | -23.56%824K | -16.97%3.98M | -22.37%1.14M |
| Research and development costs | -12.53%377K | 65.37%425K | -29.80%424K | 17.69%1.8M | 41.18%504K | 85.78%431K | -44.13%257K | 26.62%604K | 9.08%1.53M | 14.79%357K |
| Operating profit | 129.19%352K | 222.02%532K | 4.27%-1.21M | 39.31%-3.8M | 36.55%-894K | -13.77%-1.21M | 77.95%-436K | 30.40%-1.27M | 16.23%-6.27M | 38.01%-1.41M |
| Net non-operating interest income (expenses) | 33.33%-2K | 50.00%3K | -155.56%-5K | 21.05%23K | 150.00%15K | -142.86%-3K | -81.82%2K | 280.00%9K | 246.15%19K | 146.15%6K |
| Non-operating interest income | --0 | 0.00%3K | --0 | 9.52%23K | 62.50%13K | --0 | -72.73%3K | --10K | --21K | --8K |
| Non-operating interest expense | -33.33%2K | ---- | 400.00%5K | --0 | -200.00%-2K | --3K | --1K | -80.00%1K | -84.62%2K | --2K |
| Other net income (expenses) | 156.96%352K | 2,265.79%899K | -110.34%-3K | -110.77%-254K | 26.92%297K | -169.36%-618K | -72.66%38K | -97.35%29K | 190.80%2.36M | -86.08%234K |
| Gain on sale of security | 156.96%352K | 2,265.79%899K | -110.34%-3K | -110.77%-254K | 26.92%297K | -169.36%-618K | -72.66%38K | -97.35%29K | 190.80%2.36M | -86.08%234K |
| Income before tax | 138.42%702K | 462.12%1.43M | 0.65%-1.22M | -3.76%-4.03M | 50.21%-582K | -1,027.78%-1.83M | 78.33%-396K | -68.45%-1.23M | 61.47%-3.89M | -93.22%-1.17M |
| Income tax | 418K | 478K | 234K | 21,300.00%214K | 21,300.00%214K | 0 | 0 | 0 | 1K | 1K |
| Earnings from equity interest net of tax | ||||||||||
| Net income | 115.54%284K | 341.41%956K | -18.40%-1.45M | -9.23%-4.25M | 31.97%-796K | -1,027.78%-1.83M | 78.33%-396K | -68.45%-1.23M | 61.46%-3.89M | -93.39%-1.17M |
| Net income continuous operations | 115.54%284K | 341.41%956K | -18.40%-1.45M | -9.23%-4.25M | 31.97%-796K | -1,027.78%-1.83M | 78.33%-396K | -68.45%-1.23M | 61.46%-3.89M | -93.39%-1.17M |
| Noncontrolling interests | 187.00%574K | 399.19%619K | 645.24%313K | 461.60%452K | 135.14%87K | 3,233.33%200K | 236.26%124K | 153.85%42K | -184.09%-125K | 212.12%37K |
| Net income attributable to the company | 85.69%-290K | 164.81%337K | -39.13%-1.77M | -24.87%-4.7M | 26.84%-883K | -1,106.55%-2.03M | 70.05%-520K | -95.08%-1.27M | 62.54%-3.76M | -111.01%-1.21M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | 85.69%-290K | 164.81%337K | -39.13%-1.77M | -24.87%-4.7M | 26.84%-883K | -1,106.55%-2.03M | 70.05%-520K | -95.08%-1.27M | 62.54%-3.76M | -111.01%-1.21M |
| Diluted earnings per share | 85.71%-0.001 | 150.00%0.001 | 0.00%-0.005 | -6.25%-0.017 | 40.00%-0.003 | -600.00%-0.007 | 71.43%-0.002 | -66.67%-0.005 | 68.00%-0.016 | 16.67%-0.005 |
| Basic earnings per share | 85.71%-0.001 | 150.00%0.001 | 0.00%-0.005 | -6.25%-0.017 | 40.00%-0.003 | -600.00%-0.007 | 71.43%-0.002 | -66.67%-0.005 | 68.00%-0.016 | 16.67%-0.005 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Heat List
CA
Overall
Symbol
Price
% Chg
No Data